sPLA2 can enhance the expression of CD86, CD80, CD83, and CD40 on the surface of DCs, promote DC maturation, and improve the prognosis of sepsis (ClinicalTrials.gov ID NCT00034476) [175]. Here, CD86 is linked to Sepsis.